Johnson & Johnson (JNJ)

$244.44 +1.95 (0.80%)
Market Cap 584.06B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 22.26
Forward PE 20.83
Profit Margin 28.46%
Debt to Equity Ratio 0.48
Volume 7,554,100
Avg Vol 8,906,432
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 93%
Beta 0.34
Analysts Strong Sell
Price Target $243.16

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Dr_Stoxx
Dr_Stoxx Mar. 31 at 9:38 PM
$JNJ: @InvestorsBusinessDaily Stock of the Day -- looks like easy green into earnings. hashtag#IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Mar. 31 at 4:57 PM
$TAK Outstanding Phase 3 LATITUDE clinical efficacy for Zasocitinib. Generating up to 33.4% PASI 100 functionally obsoletes $AMGN Otezla. The incoming NCT06973291 head-to-head data against $BMY Sotyktu is the ultimate binary catalyst. Watch for \ $JNJ Icotyde as the primary out-of-class threat. Read more: www.clinicaltrialsdaily.com/zasocitinib-tyk2-plaque-psoriasis/
0 · Reply
hyenacorp
hyenacorp Mar. 31 at 3:49 PM
$JNJ
0 · Reply
MorganHoratio
MorganHoratio Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.
0 · Reply
Quantumup
Quantumup Mar. 31 at 11:41 AM
BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20
0 · Reply
DragonAlgo
DragonAlgo Mar. 31 at 5:52 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-02 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $2.64 Stop: $1.90 TP1: $3.43 TP2: $4.49 TP3: $6.34 🔗 https://dragonalgo.com
0 · Reply
The__short_squeezer
The__short_squeezer Mar. 30 at 8:44 PM
$NFLX $GOOG $TSLA $LLY $JNJ
0 · Reply
Lowkeyoptions
Lowkeyoptions Mar. 30 at 8:42 PM
$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.
0 · Reply
yellowstar16
yellowstar16 Mar. 30 at 7:57 PM
$JNJ been holding up well in this market.
0 · Reply
booboobeargimmy
booboobeargimmy Mar. 30 at 7:48 PM
$JNJ taking a position here
0 · Reply
Latest News on JNJ
My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 12 Buys

Mar 31, 2026, 8:15 AM EDT - 17 hours ago

My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 12 Buys

ARCC AVGO BP BX CSWC HTGC MAIN

Johnson & Johnson: The Return Of The Dividend King

Mar 31, 2026, 2:03 AM EDT - 23 hours ago

Johnson & Johnson: The Return Of The Dividend King

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 1 day ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Dividend Investing Is Winning In 2026 - Move Over, Tech And AI

Mar 30, 2026, 7:15 AM EDT - 1 day ago

Dividend Investing Is Winning In 2026 - Move Over, Tech And AI

AMZN CRM ED GOOGL MCD META MSFT

Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April

Mar 28, 2026, 10:45 PM EDT - 3 days ago

Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April

PG

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 28, 2026, 10:00 AM EDT - 3 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 4:46 PM EDT - 4 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 27, 2026, 6:31 AM EDT - 4 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios

Mar 25, 2026, 9:43 PM EDT - 6 days ago

Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

Mar 24, 2026, 8:45 AM EDT - 7 days ago

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

PTGX

Best Dividend Aristocrats As Of March 20, 2026

Mar 21, 2026, 2:12 AM EDT - 10 days ago

Best Dividend Aristocrats As Of March 20, 2026

ABT ADM ADP ALB AMCR AOS APD

The Big 3: ORCL, JNJ, SBUX

Mar 19, 2026, 1:00 PM EDT - 12 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 19, 2026, 9:35 AM EDT - 12 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 13 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 1:17 PM EDT - 13 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 8:31 AM EDT - 13 days ago

US FDA approves J&J's oral psoriasis pill

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 18, 2026, 7:49 AM EDT - 13 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 16, 2026, 11:00 AM EDT - 15 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 13, 2026, 12:35 PM EDT - 18 days ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 12, 2026, 8:00 AM EDT - 19 days ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity

Mar 11, 2026, 9:36 AM EDT - 20 days ago

Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity

AMD APD CAT DHI FISV LLY

Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 5:10 PM EDT - 21 days ago

Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 3:55 PM EST - 26 days ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

US FDA approves JNJ's blood cancer drug

Mar 5, 2026, 2:21 PM EST - 26 days ago

US FDA approves JNJ's blood cancer drug

Johnson & Johnson launches website for direct-to-consumer sales

Mar 4, 2026, 6:07 PM EST - 27 days ago

Johnson & Johnson launches website for direct-to-consumer sales

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 2:02 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Wasatch Global Value Fund Q4 2025 Performance Review

Mar 3, 2026, 1:18 PM EST - 4 weeks ago

Wasatch Global Value Fund Q4 2025 Performance Review

BABA C T VICI

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 3, 2026, 8:03 AM EST - 4 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 2, 2026, 4:30 PM EST - 4 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 4 weeks ago

Best Dividend Aristocrats For March 2026

ABBV ABT ADM ADP AFL ALB AMCR

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

Feb 26, 2026, 5:34 PM EST - 4 weeks ago

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

AWR DOV GPC PG

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 26, 2026, 2:30 PM EST - 4 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 24, 2026, 4:03 PM EST - 5 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 11:35 AM EST - 5 weeks ago

Does JNJ Stock Still Offer Value?

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:43 AM EST - 5 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 23, 2026, 10:28 AM EST - 5 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 21, 2026, 8:00 AM EST - 5 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:30 PM EST - 5 weeks ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 5:00 PM EST - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:34 PM EST - 5 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 2:11 PM EST - 5 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

2 High-Yield CEFs To Enhance Your Retirement Income

Feb 19, 2026, 9:15 AM EST - 5 weeks ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:44 AM EST - 5 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:17 AM EST - 5 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 10:15 AM EST - 5 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 18, 2026, 7:30 AM EST - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Dividend Income: Lanny's December 2025 Summary

Feb 17, 2026, 6:23 AM EST - 6 weeks ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:19 PM EST - 6 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 4:18 PM EST - 6 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Dr_Stoxx
Dr_Stoxx Mar. 31 at 9:38 PM
$JNJ: @InvestorsBusinessDaily Stock of the Day -- looks like easy green into earnings. hashtag#IBDPartner @MarketSurge @InvestorsBusinessDaily
1 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Mar. 31 at 4:57 PM
$TAK Outstanding Phase 3 LATITUDE clinical efficacy for Zasocitinib. Generating up to 33.4% PASI 100 functionally obsoletes $AMGN Otezla. The incoming NCT06973291 head-to-head data against $BMY Sotyktu is the ultimate binary catalyst. Watch for \ $JNJ Icotyde as the primary out-of-class threat. Read more: www.clinicaltrialsdaily.com/zasocitinib-tyk2-plaque-psoriasis/
0 · Reply
hyenacorp
hyenacorp Mar. 31 at 3:49 PM
$JNJ
0 · Reply
MorganHoratio
MorganHoratio Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.
0 · Reply
Quantumup
Quantumup Mar. 31 at 11:41 AM
BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20
0 · Reply
DragonAlgo
DragonAlgo Mar. 31 at 5:52 AM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-02 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $2.64 Stop: $1.90 TP1: $3.43 TP2: $4.49 TP3: $6.34 🔗 https://dragonalgo.com
0 · Reply
The__short_squeezer
The__short_squeezer Mar. 30 at 8:44 PM
$NFLX $GOOG $TSLA $LLY $JNJ
0 · Reply
Lowkeyoptions
Lowkeyoptions Mar. 30 at 8:42 PM
$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.
0 · Reply
yellowstar16
yellowstar16 Mar. 30 at 7:57 PM
$JNJ been holding up well in this market.
0 · Reply
booboobeargimmy
booboobeargimmy Mar. 30 at 7:48 PM
$JNJ taking a position here
0 · Reply
JJBurch
JJBurch Mar. 30 at 3:15 PM
$OSRH 🚨 🚨 🚨 ‼️ ‼️ 🚀 buy $OSRH ready for commercialization now!! My friends. Last call to go ALL IN $OSRH!!! $JNJ $MRK $TSLA $GCTK
0 · Reply
jmf123
jmf123 Mar. 30 at 2:21 PM
$AMGN $ICU $JNJ $MRNA $TAK I so agree. A $30 stock price would only be a $100 million market cap.
0 · Reply
SparkyReturns
SparkyReturns Mar. 30 at 2:03 PM
$ICU This is no joke. Sleeper of the century. 10M Market Cap for a company that will earn billions in revenue in a few years. Up 12% so far today on great news. $MRNA $AMGN $JNJ $TAK
0 · Reply
ArthurOwens63
ArthurOwens63 Mar. 30 at 1:59 PM
$JNJ defensive heavyweight acting like capital wants stability watch for steady trend confirmation over excitement
0 · Reply
DragonAlgo
DragonAlgo Mar. 30 at 1:32 PM
🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-02 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $2.42 Stop: $1.74 TP1: $3.15 TP2: $4.11 TP3: $5.81 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
LandonCapital
LandonCapital Mar. 30 at 11:53 AM
$JNJ https://landoncapital.net/putting-your-money-where-your-mouth-is-royalty-pharma-partners-with-jj-on-500m-drug-development-deal/
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 30 at 11:21 AM
$ELAB Bullish setup building here 👀 PMGC Holdings is a microcap biotech focused on muscle preservation and metabolic health, with assets targeting pathways like myostatin, especially relevant alongside the rise of GLP-1 weight loss drugs. 📰 Last Friday, their subsidiary NorthStrive updated a licensing agreement with MOA Life to advance EL-22 / EL-32, aimed at preventing muscle loss during GLP-1 treatments. 📰 Today. they reported 2025 annual results showing assets up ~43% YoY to ~$13.8M, signaling continued expansion of their asset base. Currently sitting around 3$, it could be interesting to see if they fill the gap to 6$. Peers: $LLY $JNJ $PFE $MRK
0 · Reply
Nasfact
Nasfact Mar. 30 at 10:35 AM
$SLS $JNJ $PFE
0 · Reply
Mamoto_Nakatoshi
Mamoto_Nakatoshi Mar. 30 at 10:21 AM
$JNJ needs more data
0 · Reply
Suite510
Suite510 Mar. 29 at 7:07 PM
$JNJ $KVUE $SPX $SPY April 13TH Jerk n Jerk back in court ordered mediation, Judges getting pissed on delays, court clogging for years fake bankruptcies and no serious settlement discussions Hope they get wacked 😂
1 · Reply
Br331
Br331 Mar. 29 at 4:01 PM
$JNJ we expect greatness this week
0 · Reply
DonCorleone77
DonCorleone77 Mar. 29 at 3:49 PM
$JNJ J&J announces new long-term 52-week data from Phase 3 Iconic-Advance 1, 2 Johnson & Johnson announced new long-term 52-week data from the Phase 3 Iconic-Advance 1 and 2 and Iconic-Lead studies, which assessed the efficacy and safety of Icotyde in the treatment of patients with moderate-to-severe plaque psoriasis. Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 These data are being presented at the 2026 American Academy of Dermatology, AAD, Annual Meeting. Icotyde achieved high levels of complete skin clearance up to Week 52 with no new safety signals: In the Icotyde treatment arms, rates of completely clear skin increased from 41% to 49% and 33% to 48% from Week 24 to Week 52 in Advance-1 and 2, respectively. Patients who switched from placebo to Icotyde at Week 16 achieved similar rates of complete skin clearance by Week 52 as those who were treated with Icotyde for the full 52 weeks. The Icotyde adverse event profile through Week 52 was consistent with that observed through Weeks 16 and 24, and no new safety signal was identified through Week 52. Icotyde overall adverse event and infection rates were lower than deucravacitinib through Week 24.
0 · Reply